• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Partial Seizure - Pipeline Review, H2 2011 - Product Image

Partial Seizure - Pipeline Review, H2 2011

  • Published: August 2011
  • 49 pages
  • Global Markets Direct

Partial Seizure - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Partial Seizure - Pipeline Review, H2 2011', provides an overview of the Partial Seizure therapeutic pipeline. This report provides information on the therapeutic development for Partial Seizure, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Partial Seizure. 'Partial Seizure - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Partial Seizure.
- A review of the Partial Seizure products under development by companies and universities/research institutes based on information READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Partial Seizure Overview
Therapeutics Development
An Overview of Pipeline Products for Partial Seizure
Partial Seizure Therapeutics under Development by Companies
Partial Seizure Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Partial Seizure Therapeutics - Products under Development by Companies
Partial Seizure Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Partial Seizure Therapeutics Development
Johnson & Johnson
Novartis AG
Eisai Co., Ltd.
Upsher-Smith Laboratories, Inc.
Marinus Pharmaceuticals, Inc.
Partial Seizure - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
E2007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carisbamate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bumetanide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BGG492 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
USL255 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ganaxolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Eicosapentaenoic Acid + Docosahexaenoic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Partial Seizure Therapeutics – Drug Profile Updates
Partial Seizure Therapeutics - Discontinued Products
Partial Seizure - Featured News
Jul 22, 2011: European Medicines Agency To Recall Vimpat 15-MG/ML Syrup
Jun 24, 2011: European Medicines Agency Accepts For Review Eisai's MAA For AMPA Receptor Antagonist Perampanel
Jun 16, 2011: Retigabine May Further Help People With Epilepsy, NICE Says
Jun 13, 2011: Valeant And GlaxoSmithKline Announce FDA Approval For Potiga
Apr 18, 2011: GSK And Valeant Respond To FDA On Ezogabine
Apr 11, 2011: Sunovion To Present STEDESA Clinical Data At AAN Annual Meeting
Apr 11, 2011: Upsher-Smith's Phase I Research Of Extended-Release Topiramate Shows Less Fluctuation In Plasma Levels
Mar 29, 2011: GSK and Valeant Receive European Authorisation for Trobalt (retigabine).
Mar 29, 2011: GSK And Valeant Receive European Authorization For Trobalt
Mar 04, 2011: U.S. FDA Approves Anti-epileptic Agent Banzel (rufinamide) Oral Suspension, 40MG/ML
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Partial Seizure, H2 2011
Products under Development for Partial Seizure – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Johnson & Johnson, 2011
Novartis AG, 2011
Eisai Co., Ltd., 2011
Upsher-Smith Laboratories, Inc., 2011
Marinus Pharmaceuticals, Inc., 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Partial Seizure Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Partial Seizure, H2 2011
Products under Development for Partial Seizure – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos